2023 Technology Showcase

March 2, 2023 from 1 – 4 p.m.

The Blackwell Inn & Pfahl Conference Center
2110 Tuttle Park Pl, Columbus, OH 43210

In-person Attendees:
  • Directions to the venue.
  • Parking details. Guests may also pay to park in any nearby surface lot or parking garage indicated on this map.
  • A networking reception will begin at 4 p.m. following the event.

Parking Map

Virtual Attendees:
  • On March 2, you can access the livestream directly from this webpage. It will appear below. You may submit questions for the Q&A sessions with the presenters using the chat.

Join us for presentations about impactful Nationwide Children’s research and technologies, an update by our licensee Sarepta Therapeutics and a keynote presentation on the role of the U.S. Food and Drug Administration (FDA) in accelerating gene and cell therapy innovation. This event will be held in person and livestreamed, virtually.

Keynote Speaker – Peter Marks, MD, PhD

Peter Marks

Director, Center for Biologics Evaluation and Research
U.S. Food and Drug Administration (FDA)

Peter Marks, MD, PhD, joined the FDA as deputy center director of the Center for Biologics Evaluation and Research in 2012 and became the center’s director in 2016. He has been integral to the FDA’s response to several public health emergencies.

Dr. Marks has taught about drug development in academic and industry settings and has authored or co-authored over 100 publications. In 2022, he was elected a member of the National Academy of Medicine.


Download Program PDF

Time is allotted for a Q&A with speakers and attendees following each presentation.

1 p.m. – Introduction

1:15 p.m. – Keynote Presentation: Moving Gene Therapy to the Next Level

Gene therapy offers tremendous promise for the treatment of both rare and common diseases. Dr. Marks will present on the FDA’s strategies for accelerating gene and cell therapy innovation, including leveraging characteristics that products have in common when possible, focusing on advancing manufacturing, maximizing expedited development pathways and fostering international collaboration, to benefit patients.


  • Peter Marks, MD, PhD
    Director, Center for Biologics Evaluation and Research
    U.S. Food and Drug Administration (FDA)

1:55 p.m. – Delivering on the Promise for Transformative Gene Medicine for Muscular Dystrophies

Sarepta Therapeutics is a precision genetic medicine company focused on bringing a better life to patients with rare neuromuscular diseases through groundbreaking work in Duchenne and limb-girdle muscular dystrophies driven by multi-platform gene therapy, RNA and gene editing technologies.

Sarepta’s work in gene therapy, rooted in Ohio at its Genetic Therapies Center of Excellence (GTCOE), represents the most promising and clinically advanced in the world. Sarepta’s goal is to continue to serve in and contribute to the Ohio biotechnology ecosystem.


  • Louise Rodino-Klapac, PhD
    Executive Vice President, Head of Research and Development and Chief Scientific Officer
    Sarepta Therapeutics, Inc., GTCOE

Louise Rodino-Klapac, PhD is a gene therapy pioneer who has dedicated her professional life to advancing medicines designed to treat genetic diseases. Now, she has established the GTCOE at Sarepta and leads its Gene Editing Innovation Center, directing a team of researchers working to discover and develop novel gene replacement and gene editing therapies.

Dr. Rodino-Klapac previously oversaw gene therapy research at Nationwide Children’s. She co-founded and served as chief scientific officer of Myonexus Therapeutics, a gene therapy company focused on limb-girdle muscular dystrophies acquired by Sarepta in 2019. Her work has led to 11 investigational new drug applications, and she is the co-inventor of SRP-9001, an investigational micro-dystrophin gene therapy, and the inventor of five investigational gene therapies for limb-girdle muscular dystrophy. She is also the inventor of over 50 U.S. and over 70 international published patent applications.

Introduction by Margaret Barkett, PhD, Licensing Director, Office of Technology Commercialization

2:15 p.m. – Exposure to P. Gingivalis Outer Membrane Vesicles Alters Neurodevelopment of Offspring in utero

Dr. Lauber will discuss how exposure to P. gingivalis outer membrane vesicles alters neurodevelopment of offspring in utero.


Introduction by Andrew Corris, PharmD, JD, Senior Licensing Associate, Office of Technology Commercialization

2:35 p.m. – The Nationwide Innovation Center Endeavor; Innovation in Nursing Practice

Drs. Criss and Landers will highlight Nationwide Children’s innovative models and discuss programming established to foster innovative ideas.


  • Cory Criss, MD
    Surgeon, General Pediatric Surgery
    Nationwide Children's Hospital
  • Timothy Landers, PhD APRN-CNP FAAN
    Nurse Scientist, Center for Nursing Excellence
    Nationwide Children’s Hospital

Introduction by Andrew Corris, PharmD, JD, Senior Licensing Associate, Office of Technology Commercialization

3:05 p.m. – Child-Resistant and Senior-Friendly Packaging Testing for Patented, Two-Stage Sprayer

Dr. McKenzie will describe the development and testing of a child-resistant and senior-friendly spray bottle for household chemicals that prevents accidental operation using a two-stage trigger system.


  • Lara McKenzie, PhD, MA, FAAHB
    Principal Investigator and Director of Training and Education, Center for Injury Research and Policy
    Nationwide Children's Hospital

Introduction by Kyle Murrah, PhD, Senior Licensing Associate, Office of Technology Commercialization

3:25 p.m. – Development and Commercialization of Organs on Chips

Drs. Besner and Mihi will discuss the development of a human intestinal organ-on-a-chip platform as a reliable alternative to pre-clinical animal testing to improve the efficiency of translating novel therapeutics from bench to bedside.


  • Gail E. Besner, MD
    Chief, H. William Clatworthy Jr. Professor of Surgery, Department of General Pediatric Surgery
    Principal Investigator, Center for Perinatal Research
    Nationwide Children's Hospital
  • Belgacem Mihi, DVM, PhD
    Research Scientist, Center for Perinatal Research
    Nationwide Children's Hospital

Introduction by Kyle Murrah, PhD, Senior Licensing Associate, Office of Technology Commercialization

3:45 p.m. – Closing Remarks

A networking reception will follow the in-person event.